PCSK9 Patent Fight: Amgen Opposes Doctor Efforts To Keep Praluent On Market
Executive Summary
Praulent prescribers try to bolster Sanofi and Regeneron’s argument of the public need for the product but Amgen says their testimony is improper; stay of permanent injunction expires Feb. 21 unless Federal Circuit extends it through appeal.
You may also be interested in...
Sanofi/Regeneron Get Reprieve: Praluent Can Stay On Market For Now
Federal Circuit stays injunction that would have halted sales of the PCSK9 inhibitor on Feb. 21; stay extends through appeal of injunction and patent verdict.
Amgen’s Repatha Passes CVOT Test, But Contribution To 2017 Sales Growth Unclear
Amgen’s PCSK9 inhibitor Repatha succeeded in the FOURIER cardiovascular outcomes study, but the data may not impact the company’s revenue until 2018 – after a potential revenue decline in 2017.
J.P. Morgan Notebook Day 1: PCSK9 Face-Off, Teva’s Slowed Growth, Merck’s Keytruda Wins, Lilly’s CDK4/6 Hopes And More
Daily round-up of news and notes from the 2017 J.P. Morgan Healthcare conference in San Francisco. Regeneron CEO rebuffs Amgen’s patent battle strategy; Teva CEO apologizes for reduced financial guidance; Merck looks for more Keytruda wins, combos; Lilly awaits potentially differentiating Phase III CDK4/6 data; Alkermes readies ALKS 5461 depression submission; Biden discusses cancer moonshot, FDA’s real world evidence views; and UniQure turns a corner.